Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
Healthcare
$1.50 +1047.56%
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
52W Low $0.62High $13.08
Volume 0.02M
Average 0.10M
Income Statement
Follow revenue through to earnings.
Revenue
$116.36M
FY 2025 · Annual
-37.6% YoYOperating Income
-$68.25M
FY 2025 · Annual
Net Income
-$69.78M
FY 2025 · Annual
Income Statement
CNY
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 214.07M | 260.27M | 211.65M | 186.36M | 116.36M |
| Cost of Revenue | 88.67M | 106.75M | 81.8M | 95.06M | 92.49M |
| Gross Profit | 125.39M | 153.52M | 129.86M | 91.3M | 23.87M |
| Gross Margin | 58.6% | 59.0% | 61.4% | 49.0% | 20.5% |
| Research & Development | 11.37M | 13.42M | 11.9M | 12.79M | 18.01M |
| Selling, General & Admin | 58.19M | 63.56M | 66.63M | 63.84M | 74.92M |
| Operating Expenses | 73.01M | 87.69M | 84.87M | 74.86M | 92.12M |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| EBITDA | 70.12M | 85.55M | 72.1M | 42.6M | (42.52M) |
| EBITDA Margin | 32.8% | 32.9% | 34.1% | 22.9% | -36.5% |
| Operating Income | 52.38M | 65.83M | 44.99M | 16.44M | (68.25M) |
| Operating Margin | 24.5% | 25.3% | 21.3% | 8.8% | -58.7% |
| Interest Income | 112K | 114K | 312K | 231K | 96K |
| Interest Expense | 1.05M | 2.84M | 4.42M | 4.04M | 3.4M |
| Other Income / Expenses | 683K | (1.92M) | (1.22M) | (2.05M) | (3.62M) |
| Income Before Tax | 53.07M | 63.91M | 43.76M | 14.39M | (71.87M) |
| Pre-Tax Margin | 24.8% | 24.6% | 20.7% | 7.7% | -61.8% |
| Income Tax Expense | 6.6M | 8.17M | 6.25M | 924K | 11.1M |
| Net Income | 38.96M | 46.74M | 31.46M | 11.31M | (69.78M) |
| Net Margin | 18.2% | 18.0% | 14.9% | 6.1% | -60.0% |
| EPS (Basic) | 0.85 | 1.02 | 0.69 | 0.24 | (1.40) |
| EPS (Diluted) | 0.83 | 0.99 | 0.67 | 0.24 | (1.40) |
| 45.67M | 45.67M | 45.67M | 47.17M | 47.35M | |
| 47.17M | 47.17M | 47.17M | 47.17M | 47.35M |
ZYBT Earnings Waterfall · TTM
NASDAQ:ZYBT · Revenue to Net Income
No earnings data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Aug 6, 2026 | |
| 6-K | 6-K filing | Jul 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Jun 25, 2026 | |
| 3 | Initial statement of beneficial ownership | Jun 25, 2026 |
How much revenue does ZYBT generate?
Zhengye Biotechnology Holding Limited (ZYBT) reported $116.36M of revenue in fiscal 2025.
Is ZYBT profitable?
Zhengye Biotechnology Holding Limited (ZYBT) reported -$69.78M of net income, with a net margin of -60.0%.
Continue the stock analysis
Jump to another research area for this company.